Arrayit Corporation (ARYC) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerArrayit Corporation (ARYC) trades at $0.00001. Arrayit Corporation develops and markets life science tools and integrated systems for genetic analysis and diagnostics. The company offers microarray technology, automated instruments, and consumables to research centers and pharmaceutical companies. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for ARYC: ARYC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Arrayit Corporation (ARYC) Healthcare & Pipeline Overview
Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for genetic variation analysis and diagnostics. The company's microarray technology and instruments serve genomic research centers, pharmaceutical companies, and academic institutions. With a focus on early disease detection, Arrayit operates in the competitive medical diagnostics and research sector.
What Is the Investment Thesis for ARYC?
Arrayit Corporation operates in the medical diagnostics and research sector, focusing on microarray technology. The company's gross margin of 49.4% indicates potential profitability in its core operations. However, the negative profit margin of -231.4% raises concerns about overall financial health. Key growth catalysts include expanding the application of its microarray technology in early disease detection and increasing sales of automated microarray instruments. Potential risks include the company's small market capitalization of $0.00B and high beta of -15.67, indicating high volatility. Investors should carefully consider the financial metrics and market position before investing.
Based on FMP financials and quantitative analysis
ARYC Key Highlights
Gross margin of 49.4% suggests potential efficiency in Arrayit's core microarray technology business.
- Negative profit margin of -231.4% raises concerns about the company's overall financial health and expense management.
- Market capitalization of $0.00B indicates the company is a micro-cap stock with associated volatility and liquidity risks.
- Beta of -15.67 suggests the stock price moves inversely and with greater magnitude than the market, indicating high volatility.
- Arrayit serves genomic research centers, pharmaceutical companies, and academic institutions, indicating a diversified customer base within the life sciences sector.
Who Are ARYC's Competitors?
ARYC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| TMO Thermo Fisher Scientific Inc. | $654.80 | +0.35% | $242B | — |
| DHR Danaher Corporation | $214.06 | +1.09% | $150B | — |
| NTRA Natera, Inc. | $410.35 | +0.46% | $58.8B | — |
| A Agilent Technologies, Inc. | $167.77 | +0.65% | $47.4B | — |
| IQV IQVIA Holdings Inc. | $258.21 | -0.96% | $42.5B | — |
| WAT Waters Corporation | $425.21 | -0.08% | $41.8B | — |
| ILMN Illumina, Inc. | $273.04 | +2.75% | $41.3B | — |
| IDXX IDEXX Laboratories, Inc. | $518.39 | +0.12% | $40.9B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARYC's Key Strengths?
Proprietary microarray printing technology
- Integrated systems for genetic variation analysis
- Established relationships with research institutions
- Specialized expertise in microarray applications
What Are ARYC's Weaknesses?
Negative profit margin
- Small market capitalization
- High beta indicating high volatility
- Limited financial resources
What Are the Key Risks for ARYC?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger companies with greater resources.
- Regulatory changes affecting the medical diagnostics industry.
- Technological advancements rendering current products obsolete.
- Economic downturns impacting research funding.
- Negative profit margin and limited financial resources.
What Are ARYC's Competitive Advantages?
- Proprietary microarray printing technology.
- Integrated systems for genetic variation analysis.
- Established relationships with research institutions and pharmaceutical companies.
- Specialized expertise in microarray technology and applications.
What Does ARYC Do?
Arrayit Corporation, founded to advance life science research and diagnostics, develops, manufactures, and markets tools and integrated systems for analyzing genetic variation and biological function. The company's core business revolves around microarray technology, which enables the analysis of DNA, protein, antibody, lipid, and carbohydrate microarrays for applications such as gene expression, genotyping, and protein profiling. Arrayit offers a range of automated microarray manufacturing instruments, including the NanoPrint, SpotBot Titan, and SpotLight CCD fluorescence scanners. These instruments cater to various research and diagnostic needs, providing solutions for high-throughput sample processing and analysis. In addition to instruments, Arrayit manufactures consumables like glass substrates, reagents, and clean room supplies. The company serves genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies worldwide. Headquartered in Sunnyvale, California, Arrayit Corporation continues to focus on developing innovative tools for early disease detection and advancing life science research.
What Products and Services Does ARYC Offer?
- Develops microarray tools and components.
- Manufactures life science tools and integrated systems.
- Markets life science tools and integrated systems.
- Offers custom printing and analysis of microarrays for research.
- Identifies and develops diagnostic microarrays for early disease detection.
- Provides automated microarray manufacturing instruments.
How Does ARYC Make Money?
- Sales of microarray tools and components to research institutions and pharmaceutical companies.
- Custom printing and analysis of microarrays for research purposes.
- Development and sales of diagnostic microarrays for early disease detection.
- Manufacturing and sales of automated microarray manufacturing instruments.
What Industry Does ARYC Operate In?
Arrayit Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market for microarray technology is driven by the need for high-throughput analysis of genetic variation and biological function. Arrayit competes with companies offering similar tools and services, including those specializing in genomics, proteomics, and diagnostics. The industry is subject to regulatory requirements and intellectual property protection, influencing the competitive landscape and market access.
Who Are ARYC's Key Customers?
- Genomic research centers
- Pharmaceutical companies
- Academic institutions
- Clinical research organizations
- Government agencies
- Biotechnology companies
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Arrayit Corporation stands at 54.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Arrayit Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO Rene A. Schena. ARYC has traded publicly since 2001.
Financial Health
Arrayit Corporation's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ARYC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ARYC Latest News
No recent news available for ARYC.
ARYC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ARYC.
Price Targets
Wall Street price target analysis for ARYC.
ARYC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ARYC; grades run from A+ (80-100) to F (below 30).
Leadership: Rene A. Schena
Managing
Rene A. Schena is the managing person at Arrayit Corporation, overseeing the company's operations and strategic direction. He is responsible for leading the company's efforts in developing, manufacturing, and marketing life science tools and integrated systems.
Track Record: Due to limited information, Rene A. Schena's specific achievements, strategic decisions, and company milestones under his leadership cannot be comprehensively assessed. However, as the managing person, he is responsible for guiding the company's activities in the competitive life sciences technology sector and managing its seven employees.
ARYC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arrayit Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor news and press releases for any updates or developments.
- Consult with a financial advisor before investing.
- Development of microarray tools and components.
- Manufacturing of life science tools and integrated systems.
- Marketing of life science tools and integrated systems.
What Investors Ask About Arrayit Corporation (ARYC) — Healthcare
What do analysts say about ARYC stock?
There is currently no available analyst coverage or consensus on Arrayit Corporation (ARYC) due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in ARYC.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to OTC listing.